AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT BETWEEN COLUCID PHARMACEUTICALS, INC. AND ELI LILLY AND COMPANY EFFECTIVE AS OF FEBRUARY 10, 2015Development and License Agreement • April 10th, 2015 • CoLucid Pharmaceuticals, Inc. • Pharmaceutical preparations • Indiana
THIS AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”), is entered into as of February 10, 2015 (the “Restatement Effective Date”), by and between COLUCID PHARMACEUTICALS, INC. (“CoLucid”), a corporation organized and existing under the laws of the State of Delaware, having its principal place of business at 902 North Capitol Avenue, Suite 302, Indianapolis, Indiana 46204, and ELI LILLY AND COMPANY (“Lilly”), a corporation organized and existing under the laws of the State of Indiana, having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285. CoLucid and Lilly are sometimes referred to herein individually as a “Party” and collectively as “Parties.” The Parties agree as follows:
and - Master Services AgreementMaster Services Agreement • April 10th, 2015 • CoLucid Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
WHEREAS, COLUCID is the owner of certain proprietary compounds and wishes to engage PCAS to manufacture and/or package, label and store for COLUCID a certain compound referred to as COL-144 (lasmiditan) and/or certain of its intermediates, or develop synthesis processes as from time to time requested by COLUCID;
